{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T22:33:10Z","timestamp":1770330790854,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["RA 1729\/2-1"],"award-info":[{"award-number":["RA 1729\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.bbmt.2016.08.024","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T22:51:08Z","timestamp":1473375068000},"page":"1988-1996","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features"],"prefix":"10.1016","volume":"22","author":[{"given":"Leo","family":"Rasche","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"R\u00f6llig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Stuhler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Danhof","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Mielke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goetz Ulrich","family":"Grigoleit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Dissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Schemmel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Moritz","family":"Middeke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktoria","family":"R\u00fccker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Schreder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Schetelig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Bornh\u00e4user","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Thiede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Knop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.08.024_bib0010","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1182\/blood-2005-09-3869","article-title":"Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma","volume":"107","author":"Garban","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0015","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2008-02-141598","article-title":"A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma","volume":"112","author":"Rosinol","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0020","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1200\/JCO.2010.32.7312","article-title":"Tandem autologous\/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up","volume":"29","author":"Bjorkstrand","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0025","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V124.21.43.43","article-title":"Autologous followed by allogeneic versus tandem-autologous stem cell transplant in newly diagnosed FISH-del13q myeloma","volume":"124","author":"Knop","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0030","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJMoa065464","article-title":"A comparison of allografting with autografting for newly diagnosed myeloma","volume":"356","author":"Bruno","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0035","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0040","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1182\/blood-2011-11-393801","article-title":"Donor versus no-donor comparison of newly diagnosed myeloma patients included in the HOVON-50 multiple myeloma study","volume":"119","author":"Lokhorst","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0045","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.3109\/10428194.2015.1052808","article-title":"When to recommend allogeneic transplant in multiple myeloma","volume":"56","author":"Gertz","year":"2015","journal-title":"Leuk Lymph"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0050","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0055","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1200\/JCO.2013.53.0329","volume":"32","author":"Moreau","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0060","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/10428194.2013.803547","article-title":"The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide","volume":"55","author":"Wang","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0065","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.8016","article-title":"Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): outcomes in pts refractory to lenalidomide (LEN) and\/or bortezomib (BORT)","volume":"30","author":"Vij","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0070","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0075","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s00277-012-1414-5","article-title":"Features of extramedullary myeloma relapse: high proliferation, minimal marrow involvement, adverse cytogenetics: a retrospective single-center study of 24 cases","volume":"91","author":"Rasche","year":"2012","journal-title":"Ann Hematol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0080","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.bbmt.2012.10.008","article-title":"Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma","volume":"19","author":"Kroger","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0085","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1600-0609.2012.01777.x","article-title":"Comparable outcomes between unrelated and related donors after reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation in patients with high-risk multiple myeloma","volume":"88","author":"El-Cheikh","year":"2012","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0090","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/bmt.2010.90","article-title":"Tandem autologous non-myeloablative allogeneic transplantation in patients with multiple myeloma relapsing after a first high dose therapy","volume":"46","author":"Karlin","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0095","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.22273","article-title":"Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma","volume":"87","author":"Bashir","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0100","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1200\/JCO.2000.18.16.3031","article-title":"Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome","volume":"18","author":"Lokhorst","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1182\/blood.V98.4.934","article-title":"T-cell\u2013depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect","volume":"98","author":"Alyea","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0110","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1182\/blood.V93.8.2748","article-title":"Chimerism following donor lymphocyte infusion for chronic myeloid leukemia","volume":"93","author":"Gardiner","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0115","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.bmt.1701119","article-title":"Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT","volume":"21","author":"Bader","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1704525","article-title":"Significance of chimerism in hematopoietic stem cell transplantation: new variations on an old theme","volume":"34","author":"Khan","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0125","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1182\/blood.V87.7.3027.bloodjournal8773027","article-title":"Patterns of hematopoietic chimerism following bone marrow transplantation for childhood acute lymphoblastic leukemia from volunteer unrelated donors","volume":"87","author":"Molloy","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0130","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.bbmt.2015.07.005","article-title":"Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0135","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/bmt.2014.158","article-title":"Quantitative chimerism: an independent acute leukemia prognosis indicator following allogeneic hematopoietic SCT","volume":"49","author":"Qin","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0140","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.bbmt.2014.12.029","article-title":"Chimerism-based pre-emptive immunotherapy with fast withdrawal of immunosuppression and donor lymphocyte infusions after allogeneic stem cell transplantation for pediatric hematologic malignancies","volume":"21","author":"Horn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0145","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/bmt.2014.2","volume":"49","author":"Solomon","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0150","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/leu.2011.234","article-title":"Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial","volume":"26","author":"Platzbecker","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0155","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.trim.2005.06.002","article-title":"Chimerism does not influence graft-versus-myeloma and graft-versus-host disease in reduced intensity setting","volume":"15","author":"Galimberti","year":"2005","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0160","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.exphem.2006.01.011","article-title":"Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantifyminimal residual disease in patients with multiple myeloma","volume":"34","author":"Kr\u00f6ger","year":"2006","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0165","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1038\/sj.bmt.1701779","article-title":"Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection","volume":"23","author":"Thiede","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/sj.leu.2401953","article-title":"Sequential monitoring of chimerism and detection of minimal residual disease after allogeneic blood stem cell transplantation (BSCT) using multiplex PCR amplification of short tandem repeat-markers","volume":"15","author":"Thiede","year":"2001","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0175","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","article-title":"International uniform response criteria for multiple myeloma","volume":"20","author":"Durie","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0180","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/bmt.2012.239","article-title":"Graft failure in the modern era of allogeneic hematopoietic SCT","volume":"48","author":"Olsson","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1182\/blood.V90.1.12.12_12_20","article-title":"Constitutive expression of Fas (Apo-1\/CD95) ligand on multiple myeloma cells: a potential mechanism of tumor-induced suppression of immune surveillance","volume":"90","author":"Villunger","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0190","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J Allerg Clin Immunol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0195","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/sj.bmt.1705582","article-title":"Chimerism analysis within 6 months of allogeneic stem cell transplantation predicts relapse in acute myeloid leukemia","volume":"39","author":"Huisman","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0200","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.bbmt.2014.07.003","article-title":"Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning","volume":"20","author":"Reshef","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0205","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.bbmt.2014.05.025","article-title":"Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival","volume":"20","author":"Koreth","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0210","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1182\/blood-2003-01-0189","article-title":"Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma","volume":"102","author":"Corradini","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/978-1-4614-9437-9_12","article-title":"Molecular methods for detection of minimal residual disease following transplantation in lymphoid and plasma cell disorders","volume":"1109","author":"Corradini","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0220","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1517\/14712598.2015.1036735","article-title":"Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs","volume":"15","author":"Festuccia","year":"2015","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0225","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.clml.2015.03.016","article-title":"Trends and outcomes in allogeneic hematopoietic stem cell transplant for multiple myeloma at Mayo Clinic","volume":"15","author":"Mir","year":"2015","journal-title":"Clin Lymph Myel Leuk"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0230","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood-2015-07-635383","article-title":"How I treat extramedullary myeloma","volume":"127","author":"Touzeau","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0235","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1038\/bcj.2015.48","article-title":"Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma","volume":"5","author":"Vincent","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0240","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/sj.leu.2404085","article-title":"Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients","volume":"20","author":"Perez-Simon","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0245","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/sj.bmt.1705982","article-title":"Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome","volume":"41","author":"Minnema","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0250","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/sj.bmt.1704713","article-title":"Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcome","volume":"34","author":"Zeiser","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0255","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0260","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.bbmt.2014.04.027","article-title":"The graft-versus-myeloma effect: chronic graft-versus-host disease but not acute graft-versus-host disease prolongs survival in patients with multiple myeloma receiving allogeneic transplantation","volume":"20","author":"Donato","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0265","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0270","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.exphem.2013.08.003","article-title":"Evolving strategies with immunomodulating drugs and tandem autologous\/allogeneic hematopoietic stem cell transplantation in first line high risk multiple myeloma patients","volume":"41","author":"Michallet","year":"2013","journal-title":"Exp Hematol"},{"key":"10.1016\/j.bbmt.2016.08.024_bib0275","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3109\/10428194.2012.656635","article-title":"Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant","volume":"53","author":"Beitinjaneh","year":"2012","journal-title":"Leuk Lymph"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116303202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116303202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:56:45Z","timestamp":1761058605000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116303202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["S1083879116303202"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.024","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Focus on Longitudinal Assessment of Donor Chimerism, Extramedullary Disease, and High-Risk Cytogenetic Features","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation.","name":"copyright","label":"Copyright"}]}}